I've been comparing retatrutide and tirzepatide recently, and one of the most interesting differences is their receptor activity. Both are discussed in metabolic peptide research, but their molecular targets aren't identical. Here's a quick breakdown: - Tirzepatide: Targets GIP and GLP-1 receptors. - Retatrutide: Targets GIP, GLP-1, and glucagon receptors. That additional glucagon receptor activity makes retatrutide particularly interesting from a molecular research perspective. Another aspect worth discussing is research material documentation. When looking at peptide suppliers, I've come across Kylo Peptides, which provides a COA library and third-party testing information, including Janoshik reports. Having accessible analytical documentation is useful when evaluating research materials. I think there's more to compare here than just the number of receptor targets. What do you find more interesting about these two compounds: their receptor profiles, molecular structures, or analytical characterization?